News of the FTC’s pending challenge to the Amgen deal sunk Horizon’s stock during early morning trading Tuesday, with the company’s shares down more than 17%.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,